Loading organizations...
§ Private Profile · Dublin, Ireland
Priothera is a technology company.
Priothera develops innovative immune modulators for the treatment of hematological malignancies. Its core product, mocravimod, is an investigational orally applied sphingosine 1 phosphate (S1P) receptor modulator designed to enhance the graft-versus-leukemia (GvL) effect while simultaneously reducing graft-versus-host disease (GvHD) in allogeneic hematopoietic cell transplantation (allo-HCT). The company aims to improve curative potential and outcomes for patients undergoing both allo-HCT and CAR T cell therapies.
The company was founded in 2020 by Florent Gros, Stephan Oehen, and Brice Suire. The founders brought their expertise to address critical unmet needs in hematological cancer treatment. Their insight centered on the potential of mocravimod's immunomodulatory properties to create a more favorable balance between therapeutic efficacy and reduced transplant-related complications, drawing on its well-characterized profile.
Priothera targets patients suffering from devastating hematological malignancies who undergo allo-HCT or CAR T cell therapy. The company's vision is to extend and enhance the quality of life for these patients, radically transforming treatment by delivering therapies that improve survival rates and ensure safer, more effective long-term outcomes compared to current standard care.
Priothera has raised $58.4M across 3 funding rounds.
Priothera has raised $58.4M in total across 3 funding rounds.
Priothera has raised $58.4M in total across 3 funding rounds.
Priothera's investors include WiSEED, Christian Kettel Thomsen, HealthCap, Manus Rogan, Earlybird Venture Capital, EQT Life Sciences, Forbion, INKEF Capital, Pontifax Venture Capital, Vivo Capital, Henry Skinner.
Priothera has raised $58.4M across 3 funding rounds. Most recently, it raised $3.5M Other Equity in September 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 17, 2025 | $3.5M Venture Round | Wiseed | — | Announced |
| Feb 23, 2022 | $19.8M Debt Financing | Christian Kettel Thomsen | — | Announced |
| Oct 1, 2020 | $35M Series A | HealthCap, Manus Rogan | Earlybird Venture Capital, EQT Life Sciences, Forbion, INKEF Capital, Pontifax Venture Capital, Vivo Capital, Henry Skinner | Announced |
Priothera is a late-stage biopharma company, not a technology company in the software or hardware sense, focused on developing mocravimod as an innovative immune modulator for hematologic cancers like acute myeloid leukemia (AML).[1][2][3] It builds an oral adjunctive therapy that enhances the curative potential of allogeneic hematopoietic cell transplantation (allo-HCT) and CAR-T cell therapies by boosting graft-versus-leukemia (GvL) effects while reducing graft-versus-host disease (GvHD) risks, serving AML patients post-transplant and addressing unmet needs in maintenance therapy.[1][2][3] The company, founded in 2020 with headquarters in Dublin and operations in France, is advancing mocravimod in a global Phase IIb/III trial (MO-TRANS) across Europe, the U.S., and Japan as of Q2 2025, backed by investors like Fountain Healthcare Partners, abrdn, and Bpifrance.[1][3]
Priothera's growth momentum includes orphan drug designations from the FDA and EMA, recent €1.7 million i-Nov funding from Bpifrance, and media recognition for its AML work, positioning it to potentially transform standards of care in hematology-oncology.[1][3][5]
Priothera was founded in 2020 by Florent Gros, who serves as CEO, drawing on his expertise to apply mocravimod's established mechanism—previously explored in other contexts—to hematologic malignancies.[1][2][3] The idea emerged from identifying gaps in allo-HCT outcomes, where GvHD limits curative potential despite GvL benefits; Gros's leadership statement highlights mocravimod as a "game-changing treatment" for blood cancers.[2] Early traction came from assembling a management team with deep experience in hematology, oncology, immunology, and cell therapies, securing backing from prominent life sciences investors including Fountain Healthcare Partners, abrdn, EarlyBird Venture Capital, BEI, Bpifrance Grand Est, and the BioInnovation Institute.[1][3] Pivotal moments include launching the MO-TRANS Phase 3 trial and gaining orphan drug status, with operations spanning France (Saint Louis site) and Ireland.[1][3][4]
Priothera rides the wave of advancing cell therapies in oncology, where allo-HCT and CAR-T show curative promise but face GvHD barriers limiting ~30-50% of AML patients' long-term success.[2][3] Timing aligns with surging demand for post-transplant maintenance—AML affects thousands annually with poor survival post-relapse—fueled by regulatory incentives like orphan status and funding (e.g., Bpifrance grants).[3][5] Market forces favoring Priothera include biopharma's shift to immune modulators, rising HCT volumes, and investor interest in late-stage assets amid ~$100B+ global oncology spend.[1][3] It influences the ecosystem by pioneering safer cell therapy combos, potentially setting new standards and enabling broader adoption of high-risk, high-reward transplants.[1][2]
Priothera is poised for Phase 3 readouts from MO-TRANS in the coming years, with positive data potentially accelerating approval and partnerships for commercialization by 2027-2028.[3] Trends like AI-optimized trials, expanded CAR-T indications, and precision hematology will amplify its impact, especially if mocravimod proves scalable across malignancies.[2] Its influence could evolve from niche innovator to standard-of-care leader, transforming AML survival and quality of life—delivering on its "Pursuing More Time For Life" mission amid a biotech funding rebound.[1][2] This positions Priothera as a high-conviction play in hematologic cancer breakthroughs.